Amgen, a company focusing on biotechnology, discovering, developing, manufacturing, and delivering innovative medicines, has announced plans to establish a new technology and innovation site in Hyderabad, India, to accelerate digital capabilities across its global operations.
The site, named Amgen India, will support the advancement of Amgen’s drug pipeline and is expected to be operational by Q4 2024.
Located in HITEC City, Hyderabad, the facility will span six floors of the RMZ Spire Tower 110, accommodating up to 3,000 employees. Hyderabad was selected for its strong talent pool in medicine, life sciences, data sciences, and AI.
David M. Reese, M.D., executive vice president and CTO at Amgen, highlighted the significance of the new site, stating, “At a time when a quickly aging global population needs more innovation, the convergence of biotechnology and technology is enabling Amgen to work with greater speed, confidence, and efficiency — an incredibly exciting milestone for which we have been preparing for over a decade.”
Amgen India will focus on developing new technology solutions and digital capabilities to enhance operational efficiencies across the enterprise. The site will create roles in AI, data science, life science, and other global capabilities as the operation expands.
Som Chattopadhyay has been appointed as the national executive for India, leading the expanded operations.
Telangana Chief Minister Sri Anumula Revanth Reddy welcomed the development, stating, “We are proud to welcome a global trailblazer of the biotechnology industry. Amgen’s unwavering mission to serve patients will be incredibly inspiring for the world-class technology talent seeking to make a meaningful impact on people around the world.”
Amgen, with nearly 27,000 employees, has a global presence in approximately 100 countries and regions, including India.
With more than 40 years in the industry, Amgen continues to advance a broad pipeline of treatments for cancer, heart disease, osteoporosis, inflammatory diseases, and rare conditions.
Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.
Comments are closed, but trackbacks and pingbacks are open.